Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2971760 | The Journal of Heart and Lung Transplantation | 2011 | 8 Pages |
Abstract
This study provides evidence for successful conversion from tacrolimus BID to QD on a 1:1 (mg/mg) total daily dose basis. Approximately one-third of patients may require dose adjustments. Both formulations were well tolerated, with stable renal function during the study. Adverse events were reported by approximately one-tenth of patients receiving tacrolimus BID and a quarter of those who received QD.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Rita PharmD, Johan MD, PhD, Nizar MD, FRCS (CTh), Michel MD, FRCPC, FESC, Haissam MD, FRCPC, Gregorio MD, FETCS, Wayne MD, FRCP, Beatriz Diaz PhD, Michael MD, Hans DmSci, Carmen PhD, Nasrullah PhD,